Mahender Surakanti, MD
Psychiatry · Fort Wayne, INNPI 1417940909
Payments from drug & device makers
Across 761 payments — averaging $16.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lundbeck LLC$2K
- AbbVie$2K
- Teva Pharmaceuticals USA, Inc.$1K
- Supernus Pharmaceuticals, Inc.$1K
- Alkermes, Inc.$954
- Otsuka America Pharmaceutical, Inc.$932
- plus $5K from 23 others
What the payments were for
- Food & beverage$12,49998%
- Education$2142%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lundbeck LLC | 107 | $1,665 |
| AbbVie(2 entities) | 131 | $1,581 |
| Teva Pharmaceuticals USA, Inc. | 70 | $1,482 |
| Supernus Pharmaceuticals, Inc. | 70 | $1,008 |
| Alkermes, Inc. | 56 | $954 |
| Otsuka America Pharmaceutical, Inc. | 50 | $932 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 41 | $881 |
| Neurocrine Biosciences, Inc. | 42 | $861 |
| Corium, LLC | 23 | $512 |
| Vanda Pharmaceuticals Inc. | 25 | $452 |
| Sunovion Pharmaceuticals Inc. | 24 | $323 |
| Adlon Therapeutics L.p. | 17 | $298 |
| Indivior Inc. | 14 | $260 |
| Ironshore Pharmaceuticals Inc. | 22 | $257 |
| Johnson & Johnson | 11 | $225 |
| Axsome Therapeutics, Inc. | 9 | $209 |
| E.r. Squibb & Sons, L.L.C. | 16 | $203 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $148 |
| Noven Therapeutics, LLC | 5 | $84 |
| Merck | 4 | $60 |
| Idorsia Pharmaceuticals US Inc | 3 | $51 |
| Collegium Pharmaceutical, Inc. | 2 | $46 |
| Acadia Pharmaceuticals Inc | 2 | $42 |
| Shire North American Group Inc | 2 | $38 |
| Avanir Pharmaceuticals, Inc. | 2 | $37 |
| Tris Pharma Inc | 2 | $37 |
| Noven Pharmaceuticals, Inc. | 1 | $35 |
| Lilly USA, LLC | 1 | $18 |
| Brainsway USA Inc | 1 | $14 |
How this compares
$12,713 in reported general payments places this provider in the 90th percentile of 514 psychiatry providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 25 | $177,225 |
| Invega SustennaPaliperidone Palmitate | 35 | $101,663 |
| LybalviOlanzapine/Samidorphan Malate | 47 | $73,619 |
| RexultiBrexpiprazole | 35 | $66,576 |
| Risperdal ConstaRisperidone Microspheres | 48 | $64,325 |
| VraylarCariprazine Hcl | 24 | $34,904 |
| Risperidone ErRisperidone Microspheres | 19 | $27,681 |
| CaplytaLumateperone Tosylate | 17 | $25,145 |
| Aripiprazole | 145 | $19,318 |
| TrintellixVortioxetine Hydrobromide | 14 | $15,275 |
| Divalproex Sodium ErDivalproex Sodium | 144 | $15,178 |
| Olanzapine | 286 | $13,723 |
| Ziprasidone Hcl | 109 | $13,686 |
| Clozapine | 119 | $13,243 |
| Lurasidone Hcl | 71 | $12,985 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $1,482 | $177,22525 claims |
| Johnson & JohnsonInvega Sustenna, Risperdal Consta | $225 | $165,98883 claims |
| Alkermes, Inc.Lybalvi | $954 | $73,61947 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $932 | $66,57635 claims |
| AbbVieVraylar | $1,581 | $34,90424 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $881 | $25,14517 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $148 | $15,27514 claims |
| Lilly USA, LLCOlanzapine | $18 | $13,723286 claims |
| MerckBelsomra | $60 | $5,05612 claims |
| Indivior Inc.Suboxone | $260 | $3,44713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 514 psychiatry providers in Indiana.
Other psychiatry in Fort Wayne
- Larry LambertsonFort Wayne$208K
- Prevesh RustagiFort Wayne$64K
- Geeta BishtFort Wayne$11K
- Andrea NaaumFort Wayne$8K
- Steven PaulCarmel$2.9M
- Jay FawverAngola$1.4M
- Suhayl NasrMichigan City$788K
- Christopher BojrabCarmel$714K
- Joseph FanelliMunster$443K
- Anantha ShekharIndianapolis$433K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.